Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Cao, Hui Hui ^a,b   Chu, Jian Hong ^a   Kwan, Hiu Yee ^a   Su, Tao ^a   Yu, Hua ^a   Cheng, Chi Yan ^a   Fu, Xiu Qiong ^a   Guo, Hui ^a   Li, Ting ^a   Tse, Anfernee Kai Wing ^a   Chou, Gui Xin ^c   Mo, Huan Biao ^d   Yu, Zhi Ling ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APIGENIN; GELATINASE A; GELATINASE B; SMALL INTERFERING RNA; STAT3 PROTEIN; TWIST RELATED PROTEIN 1; VASCULOTROPIN A;

ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL MOTION; DOWN REGULATION; DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; FLUORESCENCE MICROSCOPY; GENETICS; HUMAN; IMMUNOBLOTTING; LUNG TUMOR; MELANOMA; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; PREVENTION AND CONTROL; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SECONDARY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; APIGENIN; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; IMMUNOBLOTTING; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELANOMA; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; NEOPLASM INVASIVENESS; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TWIST-RELATED PROTEIN 1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84959432630     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep21731     Document Type: Article

References (61)

1. Orgaz, J. L. & Sanz-Moreno, V. Emerging molecular targets in melanoma invasion and metastasis. Pigment Cell Melanoma Res 26, 39-57, (2013).
2. DeSantis, C. E. et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64, 252-271, (2014).
3. Hauschild, A. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365, (2012).
4. Callahan, M. K., Postow, M. A. & Wolchok, J. D. Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol 31, 191-199, (2013).
5. Poust, J. C., Woolery, J. E. & Green, M. R. Management of toxicities associated with high-dose interleukin-2 and biochemotherapy. Anticancer Drugs 24, 1-13, (2013).
6. Sullivan, R. J. & Flaherty, K. T. Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer 49, 1297-1304, (2013).
7. Kortylewski, M., Jove, R. & Yu, H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 24, 315-327, (2005).
8. Xie, T. X. et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 66, 3188-3196, (2006).
9. Niu, G. et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21, 2000-2008, (2002).
10. Niu, G. et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21, 7001-7010, (2002).
11. Liu, L. et al. 6-Bromoindirubin-3′-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells. Cancer Res 71, 3972-3979, (2011).
12. Yu, H. & Jove, R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 4, 97-105, (2004).
13. Xie, T. X. et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23, 3550-3560, (2004).
14. Kamran, M. Z. & Gude, R. P. Pentoxifylline inhibits melanoma tumor growth and angiogenesis by targeting STAT3 signaling pathway. Biomed Pharmacother 67, 399-405, (2013).
15. Martinez, M. E., Marshall, J. R. & Giovannucci, E. Diet and cancer prevention: the roles of observation and experimentation. Nat Rev Cancer 8, 694-703, (2008).
16. Tong, L. X. & Young, L. C. Nutrition: the future of melanoma prevention? J Am Acad Dermatol 71, 151-160, (2014).
17. Shukla, S. & Gupta, S. Apigenin: a promising molecule for cancer prevention. Pharm Res 27, 962-978, (2010).
18. Birt, D. F., Mitchell, D., Gold, B., Pour, P. & Pinch, H. C. Inhibition of ultraviolet light induced skin carcinogenesis in SKH-1 mice by apigenin, a plant flavonoid. Anticancer Res 17, 85-91 (1997).
19. Caltagirone, S. et al. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer 87, 595-600, (2000).
20. Piantelli, M. et al. Flavonoids inhibit melanoma lung metastasis by impairing tumor cells endothelium interactions. J Cell Physiol 207, 23-29, (2006).
21. Arango, D. et al. Molecular basis for the action of a dietary flavonoid revealed by the comprehensive identification of apigenin human targets. Proc Natl Acad Sci USA 110, E2153-2162, (2013).
22. Seo, H. S. et al. Induction of caspase-dependent apoptosis by apigenin by inhibiting STAT3 signaling in HER2-overexpressing MDAMB-453 breast cancer cells. Anticancer Res 34, 2869-2882, (2014).
23. Ruela-de-Sousa, R. R. et al. Cytotoxicity of apigenin on leukemia cell lines: implications for prevention and therapy. Cell Death Dis 1, e19, (2010).
24. Liu, L. et al. A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signaling. Cancer Biol Ther 13, 1255-1261, (2012).
25. Menon, L. G., Kuttan, R. & Kuttan, G. Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds. Cancer Lett 95, 221-225 (1995).
26. He, J. et al. Oral administration of apigenin inhibits metastasis through AKT/P70S6K1/MMP-9 pathway in orthotopic ovarian tumor model. Int J Mol Sci 13, 7271-7282, (2012).
27. Weng, C. J. & Yen, G. C. Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo antimetastatic activities. Cancer Metastasis Rev 31, 323-351, (2012).
28. Clere, N., Faure, S., Martinez, M. C. & Andriantsitohaina, R. Anticancer properties of flavonoids: roles in various stages of carcinogenesis. Cardiovasc Hematol Agents Med Chem 9, 62-77, (2011).
29. Yamazaki, H. et al. Overexpression of the miR-34 family suppresses invasive growth of malignant melanoma with the wild-type p53 gene. Exp Ther Med 3, 793-796, (2012).
30. Al Zaid Siddiquee, K. & Turkson, J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 18, 254-267, (2008).
31. Bastid, J., Ciancia, C., Puisieux, A. & Ansieau, S. Role of twist proteins in cancer progression. Atlas Genet Cytogenet Oncol Haematol 14, 898-907 (2010).
32. Lo, H. W. et al. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 67, 9066-9076, (2007).
33. Kang, Y. & Massague, J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118, 277-279, (2004).
34. Kalluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal transition. J Clin Invest 119, 1420-1428, (2009).
35. Radisky, D. C. Epithelial-mesenchymal transition. J Cell Sci 118, 4325-4326, (2005).
36. Cao, H. H. et al. Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling. Biochem Pharmacol 87, 424-434, (2014).
37. Fu, X. Q. et al. Inhibition of STAT3 signalling contributes to the antimelanoma action of atractylenolide II. Exp Dermatol 23, 855-857, (2014).
38. Tse, A. K. et al. The herbal compound cryptotanshinone restores sensitivity in cancer cells that are resistant to the tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 288, 29923-29933, (2013).
39. Singh, P., Mishra, S. K., Noel, S., Sharma, S. & Rath, S. K. Acute exposure of apigenin induces hepatotoxicity in Swiss mice. PLoS One 7, e31964, (2012).
40. Gupta, S., Afaq, F. & Mukhtar, H. Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem Biophys Res Commun 287, 914-920, (2001).
41. Zhang, J., Liu, D., Huang, Y., Gao, Y. & Qian, S. Biopharmaceutics classification and intestinal absorption study of apigenin. Int J Pharm 436, 311-317, (2012).
42. Gradolatto, A. et al. Pharmacokinetics and metabolism of apigenin in female and male rats after a single oral administration. Drug Metab Dispos 33, 49-54, (2005).
43. Shukla, S. et al. Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway. Carcinogenesis 35, 452-460, (2014).
44. Zhang, J., Huang, Y., Liu, D., Gao, Y. & Qian, S. Preparation of apigenin nanocrystals using supercritical antisolvent process for dissolution and bioavailability enhancement. Eur J Pharm Sci 48, 740-747, (2013).
45. Arsic, I. et al. Preparation of novel apigenin-enriched, liposomal and non-liposomal, antiinflammatory topical formulations as substitutes for corticosteroid therapy. Phytother Res 25, 228-233, (2011).
46. Ding, S. M. et al. Enhanced bioavailability of apigenin via preparation of a carbon nanopowder solid dispersion. Int J Nanomedicine 9, 2327-2333, (2014).
47. Prasad, S., Pandey, M. K., Yadav, V. R. & Aggarwal, B. B. Gambogic acid inhibits STAT3 phosphorylation through activation of protein tyrosine phosphatase SHP-1: potential role in proliferation and apoptosis. Cancer Prev Res (Phila) 4, 1084-1094, (2011).
48. Rotte, A., Martinka, M. & Li, G. MMP2 expression is a prognostic marker for primary melanoma patients. Cell Oncol (Dordr) 35, 207-216, (2012).
49. Nikkola, J. et al. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 11, 5158-5166, (2005).
50. Zetter, B. R. Angiogenesis and tumor metastasis. Annu Rev Med 49, 407-424, (1998).
51. Ascierto, P. A. et al. Prognostic value of serum VEGF in melanoma patients: a pilot study. Anticancer Res 24, 4255-4258 (2004).
52. Wei, L. H. et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 22, 1517-1527, (2003).
53. Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9, 798-809, (2009).
54. Yu, H., Kortylewski, M. & Pardoll, D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7, 41-51, (2007).
55. Weiss, M. B. et al. TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells. Cancer Res 72, 6382-6392, (2012).
56. Hu, L., Roth, J. M., Brooks, P., Ibrahim, S. & Karpatkin, S. Twist is required for thrombin-induced tumor angiogenesis and growth. Cancer Res 68, 4296-4302, (2008).
57. Singh, S., Mak, I. W., Handa, D. & Ghert, M. The Role of TWIST in Angiogenesis and Cell Migration in Giant Cell Tumor of Bone. Advances in Biology 2014 (2014).
58. Yu, L. et al. TWIST expression in hypopharyngeal cancer and the mechanism of TWIST-induced promotion of metastasis. Oncol Rep 27, 416-422, (2012).
59. Puisieux, A., Valsesia-Wittmann, S. & Ansieau, S. A twist for survival and cancer progression. Br J Cancer 94, 13-17, (2006).
60. Yan, Y. et al. Effects of sesquiterpenes isolated from largehead atractylodes rhizome on growth, migration, and differentiation of B16 melanoma cells. Integr Cancer Ther 10, 92-100, (2011).
61. Xie, Q. et al. Recombinant adenovirus snake venom cystatin inhibits the growth, invasion, and metastasis of B16F10 cells in vitro and in vivo. Melanoma Res 23, 444-451, (2013).